Hepatitis C virus therapeutics: Editing
β
Anna Alisi; Sara Tomaselli; Clara Balsano; Angela Gallo
π
Article
π
2011
π
John Wiley and Sons
π
English
β 320 KB
I can hardly share the passionate enthusiasm of Breuhahn et al. for the ''dramatic'' improvements in understanding of molecular pathogenesis of hepatocellular carcinoma (HCC) and the claim for ''further rationally designed clinical trials based on molecular evidence''. 1 Among the causes of HCC, the